AZN - AstraZeneca PLC

NYSE - NYSE Delayed Price. Currency in USD
34.78
+0.13 (+0.38%)
At close: 4:03PM EDT

34.61 -0.17 (-0.50%)
Pre-Market: 4:30AM EDT

Stock chart is not supported by your current browser
Previous Close34.65
Open34.58
Bid34.55 x 5100
Ask34.58 x 1800
Day's Range34.49 - 34.89
52 Week Range25.55 - 35.60
Volume6,444,751
Avg. Volume5,013,927
Market Cap83.85B
Beta0.65
PE Ratio (TTM)22.81
EPS (TTM)N/A
Earnings DateN/A
Dividend & Yield0.90 (2.63%)
Ex-Dividend Date2017-08-09
1y Target EstN/A
Trade prices are not sourced from all markets
  • Reuters2 hours ago

    Astra and Merck win speedy review for Lynparza in breast cancer

    U.S. regulators have granted a priority review to AstraZeneca's ovarian cancer drug Lynparza as a treatment for breast cancer, putting it on track for potential approval in the new disease area during the first quarter of 2018. The medicine, which is being jointly developed and marketed with Merck under a deal struck in July, is the first poly ADP-ribose polymerase (PARP) drug to be considered for use outside ovarian cancer. Lynparza is also being tested in prostate and pancreatic cancers, the two companies said on Wednesday.

  • Foreign Stock Roundup: Roche Gets FDA Nod for Zika Test, Shell to Buy NewMotion
    Zacks2 days ago

    Foreign Stock Roundup: Roche Gets FDA Nod for Zika Test, Shell to Buy NewMotion

    Foreign markets remain undeterred by discouraging events, notching up weekly gains.

  • Bloomberg2 days ago

    Drug Companies Fear Brexit Will Hit Medicine Trade

    Time is running short for a Brexit agreement that will allow the free movement of medicines through the U.K. and the rest of the European Union.

  • 5 Large-Cap Drug Stocks Well Poised to Beat on Q3 Earnings
    Zacks4 days ago

    5 Large-Cap Drug Stocks Well Poised to Beat on Q3 Earnings

    The pharma/biotech sector has a number of things going in its favor.

  • Cancer Space Update: Lung & Breast Cancer Studies in Focus
    Zacks5 days ago

    Cancer Space Update: Lung & Breast Cancer Studies in Focus

    While Lilly announced failure of a lung cancer study, AstraZeneca's Tagrisso was granted Breakthrough therapy status as first-line treatment for a lung cancer indication.

  • Lilly's Verzenio Gets Priority Review in First-Line Setting
    Zacks5 days ago

    Lilly's Verzenio Gets Priority Review in First-Line Setting

    Eli Lilly and Company (LLY) announced that the FDA has granted priority review to its new drug application for Verzenio (abemaciclib) for the first-line treatment of advanced breast cancer.

  • AstraZeneca's Tagrisso Gets Breakthrough Therapy Designation
    Zacks9 days ago

    AstraZeneca's Tagrisso Gets Breakthrough Therapy Designation

    AstraZeneca (AZN) obtained Breakthrough Therapy Designation (BTD) for Tagrisso (osimertinib) for the 1st-line treatment of patients with metastatic epidermal growth factor receptor mutation-positive non-small cell lung cancer.

  • Financial Times9 days ago

    [$$] AstraZeneca chief confident risks will pay off

    Pascal Soriot is the first to recognise that a pharmaceutical company must take risks if it is to find the next transformative medicine. "It would be much simpler to sell toothbrushes and toothpastes ...

  • What's Behind AstraZeneca's September Rebound?
    Motley Fool10 days ago

    What's Behind AstraZeneca's September Rebound?

    AstraZeneca's shares finally broke out of their slump in September.

  • These Biotechs Slump As Report Suggests Discounting Their Drugs
    Investor's Business Daily14 days ago

    These Biotechs Slump As Report Suggests Discounting Their Drugs

    AstraZeneca and Tesaro stocks were in a slump Tuesday, a day after an institute doubted the cost-effectiveness of their cancer drugs.

  • Tell us how Brexit will work, British companies demand
    Reuters16 days ago

    Tell us how Brexit will work, British companies demand

    British companies including pharmaceuticals giant AstraZeneca urged the government on Monday to agree a three-year Brexit transitional deal to ease the uncertainty hampering investment decisions and the economy. Britain's biggest companies have become increasingly alarmed by the slow progress of Brexit negotiations and the prospect the country could crash out of the world's biggest trading bloc without a deal in 2019. Prime Minister Theresa May vowed in a speech last month to seek a two-year transition deal to help reduce the disruption, but her efforts were overshadowed by a challenge from Foreign Secretary Boris Johnson who has set out his own terms for Britain leaving the European Union.

  • Reuters16 days ago

    Drugs firm AstraZeneca wants three-year Brexit transition

    British pharmaceuticals giant AstraZeneca (AZN.L) wants a transition period of at least three years when Britain leaves the European Union in 2019 and more clarity on what will happen in the longer term, its chairman said on Monday. Uncertainty about what Britain's relations with the EU will look like after March 2019 are hurting investment in the world's fifth largest economy. AstraZeneca Chairman Leif Johansson said the firm wanted "at least three years" as a transition period, "and very early in that period, we need to know what to expect in years four, five and six," he said told the Swedish daily Dagens Nyheter.

  • Drugs firm AstraZeneca wants three-year Brexit transition
    Reuters16 days ago

    Drugs firm AstraZeneca wants three-year Brexit transition

    British pharmaceuticals giant AstraZeneca (AZN.L) wants a transition period of at least three years when Britain leaves the European Union in 2019 and more clarity on what will happen in the longer term, its chairman said on Monday. Uncertainty about what Britain's relations with the EU will look like after March 2019 are hurting investment in the world's fifth largest economy. AstraZeneca Chairman Leif Johansson said the firm wanted "at least three years" as a transition period, "and very early in that period, we need to know what to expect in years four, five and six," he said told the Swedish daily Dagens Nyheter.

  • Should You Be Tempted To Buy AstraZeneca PLC (LSE:AZN) At Its Current Price?
    Simply Wall St.19 days ago

    Should You Be Tempted To Buy AstraZeneca PLC (LSE:AZN) At Its Current Price?

    AstraZeneca PLC (LSE:AZN) is trading with a trailing P/E of 21.6x, which is lower than the industry average of 38.5x. While AZN might seem like an attractive stock to buy,Read More...

  • AstraZeneca's Bevespi Improves Lung Function in Phase III Study
    Zacks21 days ago

    AstraZeneca's Bevespi Improves Lung Function in Phase III Study

    AstraZeneca plc (AZN) announced top-line data from a late stage study, which showed that its Bevespi Aerosphere led to a statistically significant improvement in lung function in patients with COPD.

  • 3 High-Yield Stocks for Aggressive Investors
    Motley Fool23 days ago

    3 High-Yield Stocks for Aggressive Investors

    This drugmaker, telecom, and energy company all sport sky-high yields.

  • 12 Flu Season Facts You Need to Know
    Motley Fool24 days ago

    12 Flu Season Facts You Need to Know

    Here's everything you've ever wanted to know about influenza and flu vaccines.

  • AstraZeneca Stock Upgraded: What You Need to Know
    Motley Fool26 days ago

    AstraZeneca Stock Upgraded: What You Need to Know

    Bernstein sees opportunity in a buyout target.

  • Implied Volatility Surging for AstraZeneca (AZN) Stock Options
    Zacks28 days ago

    Implied Volatility Surging for AstraZeneca (AZN) Stock Options

    AstraZeneca (AZN) needs Investors to pay close attention to the stock based on moves in the options market lately.

  • 3 High-Yield Pharmaceutical Stocks
    Motley Fool29 days ago

    3 High-Yield Pharmaceutical Stocks

    On the hunt for a fat dividend yield? These three big pharma stocks deliver.

  • Oncology Space in Focus this Week on ESMO Presentations
    Zackslast month

    Oncology Space in Focus this Week on ESMO Presentations

    There were multiple presentations at European Society for Medical Oncology 2017 Congress. AstraZeneca's lung cancer study data was positive and so was Bristol-Myers's melanoma candidate.

  • AstraZeneca Sells Remaining Rights to its Anaesthetics Drugs
    Zackslast month

    AstraZeneca Sells Remaining Rights to its Anaesthetics Drugs

    AstraZeneca (AZN) recently sold its remaining rights to its anaesthetics medicines to Aspen Group for an upfront consideration of $555 million.

  • Reuterslast month

    Moderna, AstraZeneca heart drug succeeds early-stage trial

    Biotech unicorn Modern Therapeutics said on Thursday its heart drug, developed along with British drugmaker AstraZeneca, met the main goal in an early-stage trial. The company, which develops drugs based ...